Acadia Pharma Stock Soars 12% on Key EU Approval News

Acadia Pharmaceuticals (ACAD) shares catapulted higher, gaining over 12% in a single day. This surge has pushed the stock close to its 52-week high from late last year.

The rally was triggered by a major regulatory milestone in Europe. The European Medicines Agency's key committee recommended approving Acadia's drug, Daybue, for treating the neurobehavioral symptoms of Rett syndrome.

Daybue is one of only two drugs Acadia currently has on the market. In the first quarter, it generated $101 million in sales, showing a strong 20% year-over-year growth.

If the European Commission follows the committee's recommendation, Daybue would become the first-ever treatment approved in Europe specifically for this purpose, opening up an entirely new market for the company.

For a company of Acadia's size—with a market cap under $5 billion—gaining access to the European market represents a meaningful expansion of its revenue potential. It diversifies the company's geographic footprint beyond the United States.

Acadia operates in a niche but defensible position. It focuses on rare neurological and psychiatric conditions, like Rett syndrome and psychosis related to Parkinson's and Alzheimer's, where competition is minimal. This regulatory win reinforces its leadership in these underserved markets.

Critically, the company is already profitable, which is rare for a biotech of its scale. This financial stability, combined with a pipeline of other promising drug trials, reduces some of the inherent risk in the sector.

While the stock's sharp jump may cause short-term volatility as some traders take profits, the fundamental story has strengthened. The EU approval pathway is now clear, providing a tangible catalyst for future growth.